MX2009008118A - Polipeptido e2 del virus del papiloma usado para vacunacion. - Google Patents

Polipeptido e2 del virus del papiloma usado para vacunacion.

Info

Publication number
MX2009008118A
MX2009008118A MX2009008118A MX2009008118A MX2009008118A MX 2009008118 A MX2009008118 A MX 2009008118A MX 2009008118 A MX2009008118 A MX 2009008118A MX 2009008118 A MX2009008118 A MX 2009008118A MX 2009008118 A MX2009008118 A MX 2009008118A
Authority
MX
Mexico
Prior art keywords
papillomavirus
polypeptide
nucleotide
vector
vaccination
Prior art date
Application number
MX2009008118A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Marc Balloul
Nathalie Silvestre
Martine Baudin
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MX2009008118A publication Critical patent/MX2009008118A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2009008118A 2007-01-30 2008-01-29 Polipeptido e2 del virus del papiloma usado para vacunacion. MX2009008118A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07360004 2007-01-30
EP07360018 2007-05-15
PCT/EP2008/051032 WO2008092854A2 (en) 2007-01-30 2008-01-29 Papillomavirus e2 polypeptide used for vaccination

Publications (1)

Publication Number Publication Date
MX2009008118A true MX2009008118A (es) 2009-10-13

Family

ID=39399907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008118A MX2009008118A (es) 2007-01-30 2008-01-29 Polipeptido e2 del virus del papiloma usado para vacunacion.

Country Status (20)

Country Link
US (1) US8420103B2 (enExample)
EP (2) EP2118292B1 (enExample)
JP (1) JP5474567B2 (enExample)
KR (1) KR101636575B1 (enExample)
CN (1) CN101617052A (enExample)
AR (1) AR065076A1 (enExample)
AT (1) ATE518958T1 (enExample)
AU (1) AU2008209759B2 (enExample)
BR (1) BRPI0806350A2 (enExample)
CA (1) CA2675355C (enExample)
CL (1) CL2008000249A1 (enExample)
DK (1) DK2118292T3 (enExample)
IL (2) IL199939A (enExample)
MX (1) MX2009008118A (enExample)
PE (1) PE20081723A1 (enExample)
PL (1) PL2118292T3 (enExample)
RU (2) RU2482189C2 (enExample)
TW (1) TW200840869A (enExample)
WO (1) WO2008092854A2 (enExample)
ZA (1) ZA200904932B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012326A (es) * 2007-05-15 2010-02-10 Transgene Sa Peptidos de señalizacion.
EP2162544B1 (en) * 2007-05-15 2013-04-17 Transgene SA Vectors for multiple gene expression
KR102216962B1 (ko) * 2011-10-12 2021-02-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10232030B2 (en) * 2013-03-12 2019-03-19 Inovio Pharmaceuticals, Inc. Vaccines for human papilloma virus and methods for using the same
WO2015149051A1 (en) * 2014-03-28 2015-10-01 The Johns Hopkins University Treatment regimen using cancer vaccines and local adjuvants and their use
CN107075521B (zh) * 2014-11-04 2021-06-08 扬森疫苗与预防公司 治疗性hpv16疫苗
US10548930B2 (en) * 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
CN109862939A (zh) * 2016-06-03 2019-06-07 埃特彼塞斯公司 用于治疗人乳头瘤病毒(hpv)相关疾病的组合物和方法
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US11012555B2 (en) * 2017-11-20 2021-05-18 International Business Machines Corporation Non-verbal sensitive data authentication
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
AU2019229653B2 (en) 2018-03-07 2025-09-11 Transgene Parapoxvirus vectors
EP3891123A4 (en) 2018-12-03 2022-12-14 Board of Regents, The University of Texas System ANALOGS OF OLIGO-BENZAMIDE AND THEIR USE IN THE TREATMENT OF CANCER
CN116200416B (zh) * 2023-02-15 2024-03-12 北京康乐卫士生物技术股份有限公司 一种基于Tac启动子的质粒表达载体构建及其用途
WO2025199501A1 (en) * 2024-03-22 2025-09-25 Gritstone Bio, Inc. Human papillomavirus (hpv) vaccines

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
WO1992015672A1 (en) 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
DE4123760C2 (de) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
WO1994012629A1 (en) * 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
SI0757717T1 (sl) * 1994-05-16 2006-08-31 Merck & Co Inc Cepivo proti papilomavirusu
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
WO1998000524A1 (fr) 1996-07-01 1998-01-08 Rhone-Poulenc Rorer S.A. Procede de production d'adenovirus recombinants
EP1707631A3 (en) 1996-11-20 2006-12-27 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
JP2001506126A (ja) 1996-12-13 2001-05-15 シェーリング コーポレイション ウイルスの精製方法
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
WO1999014377A2 (en) 1997-09-16 1999-03-25 Innogenetics N.V. Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
JP3864610B2 (ja) 1998-05-21 2007-01-10 旭硝子株式会社 水分散型撥水撥油剤組成物およびその製造方法
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
US6582693B2 (en) * 1998-11-30 2003-06-24 Lemery, S.A. De C.V. Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
AU779267B2 (en) 1998-12-31 2005-01-13 Centelion S.A.S. Method for separating viral particles
DE60010654T2 (de) 1999-02-04 2005-06-16 Geron Corp., Menlo Park Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU772611B2 (en) 1999-08-25 2004-05-06 Merck Sharp & Dohme Corp. Synthetic human papillomavirus genes
US7001596B1 (en) 1999-11-15 2006-02-21 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US20020029498A1 (en) * 2000-07-03 2002-03-14 Howard Harrison Rapid cool iron and related iron improvements
WO2002008435A1 (en) 2000-07-21 2002-01-31 Glaxo Group Limited Codon-optimized papilloma virus sequences
AU2002344190B2 (en) 2001-05-30 2007-10-18 Transgene S.A. Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2003018055A1 (en) 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papilloma virus e proteins delivered by viral vector
EA007811B1 (ru) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
AU2003290460A1 (en) 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
WO2005089164A2 (en) 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
AU2008209759A1 (en) 2008-08-07
RU2013102035A (ru) 2014-07-27
CL2008000249A1 (es) 2008-05-30
PE20081723A1 (es) 2008-12-14
RU2009130791A (ru) 2011-03-10
JP5474567B2 (ja) 2014-04-16
IL215599A (en) 2014-11-30
PL2118292T3 (pl) 2011-12-30
US20100143408A1 (en) 2010-06-10
EP2118292A2 (en) 2009-11-18
EP2390340A3 (en) 2012-02-22
US8420103B2 (en) 2013-04-16
IL199939A0 (en) 2010-04-15
TW200840869A (en) 2008-10-16
CA2675355A1 (en) 2008-08-07
AR065076A1 (es) 2009-05-13
WO2008092854A3 (en) 2008-10-30
JP2010516287A (ja) 2010-05-20
IL199939A (en) 2013-02-28
BRPI0806350A2 (pt) 2011-09-06
EP2118292B1 (en) 2011-08-03
AU2008209759B2 (en) 2013-03-21
ZA200904932B (en) 2010-04-28
RU2482189C2 (ru) 2013-05-20
CN101617052A (zh) 2009-12-30
ATE518958T1 (de) 2011-08-15
KR20090129399A (ko) 2009-12-16
KR101636575B1 (ko) 2016-07-05
CA2675355C (en) 2015-04-28
WO2008092854A2 (en) 2008-08-07
EP2390340A2 (en) 2011-11-30
IL215599A0 (en) 2011-11-30
DK2118292T3 (da) 2011-10-24

Similar Documents

Publication Publication Date Title
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
EP3452493A1 (en) Nucleic acid molecules and uses thereof
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
NZ595063A (en) Polypeptides from neisseria meningitidis
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2009002816A (es) Proteinas de fusion de albumina.
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
TW200636070A (en) Rescue of influenza virus
SG10201907522QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
NZ597601A (en) Treatment and prevention of influenza
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
WO2007048086A3 (en) Canine influenza virus and related compositions and methods of use
US10548946B2 (en) Therapeutic compositions for neutralizing type I interferons, and methods of use
JP2011523642A5 (enExample)
WO2009037183A3 (de) Nukleinsäurehaltige kosmetische und/oder pharmazeutische zubereitung zur induktion antimikrobieller peptide in epithelialen deckgeweben

Legal Events

Date Code Title Description
FG Grant or registration